These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 29258079

  • 1. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
    Kudo M.
    Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
    [Abstract] [Full Text] [Related]

  • 2. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E, Larrubia JR.
    World J Gastroenterol; 2016 Jul 28; 22(28):6469-83. PubMed ID: 27605882
    [Abstract] [Full Text] [Related]

  • 3. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K, Daud AI.
    Cancer J; 2017 Jul 28; 23(1):3-9. PubMed ID: 28114249
    [Abstract] [Full Text] [Related]

  • 4. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M.
    Oncology; 2017 Jul 28; 92 Suppl 1():50-62. PubMed ID: 28147363
    [Abstract] [Full Text] [Related]

  • 5. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J.
    Hepatology; 2021 Nov 28; 74(5):2544-2560. PubMed ID: 34036623
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H, Shen J, Lu K.
    Biochem Biophys Res Commun; 2017 Apr 29; 486(2):239-244. PubMed ID: 28254435
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ.
    Future Oncol; 2018 Sep 29; 14(22):2293-2302. PubMed ID: 29663837
    [Abstract] [Full Text] [Related]

  • 10. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
    Voutsadakis IA.
    Hepatobiliary Pancreat Dis Int; 2019 Dec 29; 18(6):505-510. PubMed ID: 31551142
    [Abstract] [Full Text] [Related]

  • 11. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC.
    Clin Lung Cancer; 2016 May 29; 17(3):232-236.e1. PubMed ID: 27265743
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.
    Gut; 2019 Sep 29; 68(9):1653-1666. PubMed ID: 30902885
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP.
    Radiat Res; 2018 Sep 29; 190(3):322-329. PubMed ID: 29949442
    [Abstract] [Full Text] [Related]

  • 18. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC.
    Clin Transl Oncol; 2019 Jun 29; 21(6):702-712. PubMed ID: 30387047
    [Abstract] [Full Text] [Related]

  • 19. Side-effects of checkpoint inhibitor-based combination therapy.
    Kourie HR, Klastersky JA.
    Curr Opin Oncol; 2016 Jul 29; 28(4):306-13. PubMed ID: 27136134
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.